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 ABSTRACT 
We have developed aggregation-induced emission (AIE) dye loaded polymer 
nanoparticles with deep-red emission for siRNA delivery to pancreatic cancer 
cells. Two US Food and Drug Administration (FDA) approved surfactant
polymers, Pluronics F127 and PEGylated phospholipid, were used to prepare 
the dye-loaded nanoparticle formulations and they can be used as nanovectors
for gene silencing of mutant K-ras in pancreatic cancer cells. The successful 
transfection of siRNA by the developed nanovectors was confirmed by the 
fluorescent imaging and quantified through flow cytometry. Quantitative real
time polymerase chain reaction (PCR) indicates that the expression of the mutant
K-ras oncogene from the MiaPaCa-2 pancreatic cancer cells has been successfully
suppressed. More importantly, our in vivo toxicity study has revealed that both 
the nanoparticle formulations are highly biocompatible in BALC/c mice. Overall,
our results suggest that the AIE dye-loaded polymer nanoparticle formulations 
developed here are suitable for gene delivery and have high potential applications




Gene therapy has emerged as a valuable medicinal 
approach for combating cancers [1, 2]. Among the 
gene therapy strategies, the RNA interference (RNAi) 
method has been extensively studied and employed 
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in cancer therapy [3]. This strategy relies on a post- 
transcriptional gene silencing process that uses a 
sequence specific double-stranded RNA to initiate the 
degradation of a targeted messenger RNA (mRNA) 
homologous. In a typical RNAi process, synthetic small 
interfering RNAs (siRNAs) are transfected into the 
cytoplasm and incorporated into a nuclease complex, 
the RNA-induced silencing complex (RISC), which 
then binds to the target mRNA and subsequently cause 
its rapid degradation [4, 5]. As a result, the mRNA 
translation is interrupted to produce functional proteins. 
The successful intracellular transfection of siRNAs is 
dependent on the siRNA carrier system. By nature, 
“naked” siRNAs are negatively charged and they are 
susceptible to nuclease-mediated degradation. Thus, 
a carrier system is needed to deliver them into the 
cells [6]. It is commonly known that viral vectors are 
useful carrier systems for gene delivery owing to 
their high transfection efficiency [1]. However, some 
studies have discovered that these vectors induced 
harmful immune responses and displayed high bio- 
safety risks for gene therapy use [7]. More recently, 
the nanomedicine research community has focused 
on engineering non-viral nanoparticle based vectors 
such as magnetic nanoparticles, metallic nanoparticles, 
quantum dots, carbon based nanoparticles and polymer 
nanoparticles for safer and more effective gene delivery 
therapy applications [7]. These nanoparticles have rich 
surface chemistries, thus allowing one to incorporate 
additional functions into the particle, such as tracking 
and imaging, co-delivery of drugs, targeted delivery 
and photothermal therapy for enhancing the overall 
therapeutic effects of gene delivery therapy [8–11]. 
The use of these nanoparticles in gene delivery has 
laid an important foundation for preparing clinical 
usable gene transfecting agents in the near future. 
Polymer based fluorescent nanoparticles have been 
extensively used in biomedical research ranging from 
imaging to drug delivery [12]. These particles can be 
prepared using simple synthesis protocols and they 
are highly biocompatible for biological use. More 
importantly, they are biodegradable and they can  
be removed from the body after completing their 
programmed tasks [13]. Typically, polymer-based 
fluorescent nanoparticles are prepared by loading 
organic π-conjugated fluorophores into the core of 
hydrophobic polymer particles. The loading fluoro-
phore concentration is a crucial parameter for 
determining the overall brightness of the nanoparticle 
formulation. At relatively low loading concentration, 
the fluorescence intensity of the nanoparticles is linearly 
dependent on the dye loading efficiency. However, as 
the dye concentration increases, the dye molecules start 
to aggregate in the particle core and this phenomena 
will lead to quenching of light emission of the dyes 
[14]. This aggregation caused quenching (ACQ) 
behavior is mainly resulted from the π–π stacking 
between the aggregated dye molecules and this has 
been a major hurdle for preparing polymer-based 
fluorescent nanoparticles with high loading dye con-
centration [15]. This obstacle has been overcome by 
Tang and coworkers using aggregated dyes [16, 17]. In 
2001, they demonstrated the process of aggregation- 
induced emission (AIE) in a silole fluorogen system 
(1-methyl-1,2,3,4,5-pentaphenyl silole), where the dye 
molecules become highly emissive in the aggregated 
form [18]. The key to this phenomenon lies in the 
chemical structure of the silole molecule where five 
phenyl peripheries are attached to one silole core 
through single-bond axes. In the non-aggregated form, 
the intracellular rotation of the peripheries is not 
confined which provides a non-radiative relaxation 
channel for the excited state to decay. However, in 
the aggregated state, the physical constraint between 
the dyes prevents the peripheries from rotating and 
inactivating the non-radiative channel and thus causing 
the aggregates to emit fluorescence. This restricted 
intramolecular rotation (RIR) theory has then been 
used to explain the highly emissive behavior of AIE 
systems and applied for developments of new AIE 
fluorogens [19–21]. Recently, we have developed a 
synthesis method to incorporate conventional ACQ 
chromophores into AIE fluorogens through covalent 
integration steps [22]. More importantly, this method 
can be used to incorporate a wide variety of ACQ 
chromophores for creating different emission wave-
lengths while inheriting the AIE feature.  
Previously, we have designed and synthesized a TPE– 
TPA–DCM compound (2-(2,6-bis((E)-4-(phenyl(4’-(1,2,2- 
triphenyl vinyl)-[1,1’-biphenyl]-4-yl)amino)styryl)-4H- 
pyran-4-ylidene)malononitrile) by conjugating the red 
emitting ACQ chromophore TPA–DCM (2-(2,6-bis((E)- 
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4-(diphenylamino)styryl)-4H-pyran-4-ylidene)malono-
nitrile) to an AIE luminogen TPE (tetraphenylethene) 
[23]. The resulting compound preserves the AIE pro-
perties and was encapsulated into cross-linked bovine 
serum albumin (BSA) nanoparticles for in vitro and in 
vivo imaging applications. In this contribution, two 
polymer-based fluorescent nanoparticle formulations 
were prepared by encapsulating the TPE–TPA–DCM 
compound with the US Food and Drug Administration 
(FDA) approved PEGylated phospholipid [24, 25] or 
tri-block copolymer Pluronic F127 [26, 27] for pancreatic 
cancer gene therapy. Synthetic siRNA molecules 
specifically targeting the mutated K-ras gene were 
complexed to the modified polymer nanoparticle 
surface through layer-by-layer assembling approach. 
The K-ras gene is reported to have the highest altera-
tion frequency in pancreatic cancers [28]. This key 
oncogene has been widely studied by the pancreatic 
cancer research community since it is associated with 
a series of downstream genes that regulate tumor cell 
proliferation, migration and invasion [29–31]. The 
siRNA-complexed nanoparticles were then used for 
the transfection of pancreatic cancer cells MiaPaCa-2. 
The successful delivery of the nanoplexes to the 
MiaPaCa-2 cells was confirmed through optical 
imaging study by monitoring the fluorescence from 
the AIE dye and the FAM-labeled siRNA molecules. 
Flow cytometry was then used to quantify the 
transfection efficiency of the siRNA-complexed nano-
particles. Through real-time polymerase chain reaction 
(PCR) experiments, we have observed that both the 
formulations were capable of suppressing the K-ras 
gene expression with efficiency as high as 70%. In 
addition to gene delivery study, we have also evaluated 
the in vitro and in vivo toxicity of the dye-loaded nano-
particle formulations. In vitro (3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay 
shows that the phospholipid micelle encapsulated 
nanoparticle formulation is slightly toxic and a cell via-
bility of 70% was observed at high dosage (2.5 μg·mL–1) 
after 48 h of treatment. On the other hand, the 
Pluronic F127 nanoparticles formulation displayed a 
much better biocompatibility when compared to 
phospholipid nanoparticle formulation. Even though 
the nanoparticles promote in vitro toxicity at high 
concentration, they are highly biocompatible in vivo. 
In our in vivo study, mice treated with both for-
mulations at a dosage of 1.5 mg·kg–1 did not show 
any adverse response over six weeks of evaluation. 
No pathological abnormalities were observed from the 
histological analysis of the major organs obtained from 
the treated mice. In the near future, we envision that 
the AIE dye-loaded polymer nanoparticles will become 
valuable tools for gene delivery therapy in vivo.  
2 Materials and methods 
2.1 Nanoparticle preparation and characterization 
The AIE dye TPE–TPA–DCM was synthesized accor-
ding to our previous method [23]. To fabricate the 
nanoparticles, mPEG-DSPE-5000 (1,2-diacyl-sn-glycero- 
3-phosphoethanolamine-N-[methoxy(polyethylene  
glycol)], Laysan Bio Inc.) was mixed with the AIE dye 
in chloroform in weight ratios of 9:1 and 19:1 in a 
round bottom flask. The chloroform was then gently 
removed by a vacuum rotary evaporator with a room 
temperature water bath. After that, 10 mL of water 
was added to the lipidic layer and the flask was gently 
stirred for 20 min. The resulting mixture was then 
filtered through a 0.2 μm syringe filter to remove large 
aggregates. This results in phospholipid encapsulated 
AIE dye nanoparticles with loading ratios of 10% or 
5%. A similar procedure was used for the preparation 
of the Pluronic F127 (BASF Corp., Wyandotte, MI) 
encapsulated nanoparticles simply by replacing mPEG- 
DSPE-5000 with Pluronic F127. For siRNA conjugation, 
the nanoparticles were first coated with a thin layer 
of PAH (poly(allylamine hydrochloride, Mw = 15 kDa, 
Sigma-Aldrich) and centrifuged at 15,000 rpm for 
30 min. The pellet was then collected for siRNA 
conjugation through electrostatic absorption. The 
absorption spectra of the dye nanoparticles were 
collected using a Shimadzu model UV-2450 spectro-
photometer, where corresponding solvents were 
used as references. The photoluminescence emission 
spectra were collected by a Fluorolog-3 spectrofluoro-
meter (Edison, NJ USA). To estimate the fluorescent 
quantum yield (QY) of the nanoparticle formulations, 
integrated emission spectra of diluted nanoparticle 
suspensions were compared with rhodamine 6G. The 
absorptions were matched at the excitation wavelength 
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of 500 nm. The hydrodynamic size distribution and 
zeta potential of the nanoparticles were measured 
using the 90Plus particle analyzer (Brookhaven 
Instruments). All measurements were carried out at 
room temperature. 
2.2 Cell culture and viability studies 
MiaPaCa-2 (ATCC NO: CRL-1420) cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM, 
Life Technologies) supplemented with 10% fetal bovine 
serum (FBS). The cells were cultured at 37 °C in a 
humidified atmosphere with 5% CO2. Cell viability 
was measured by the MTT (Sigma) assay kit as 
previously described [32]. Briefly, in each assay, 5,000 
cells were dispensed into each well of a 96-well 
flat-bottom Microtiter plate and cultured overnight. 
Eight sets were treated with different concentrations 
of nanoparticle formulations and one set was treated 
with PBS buffer as the non-treated control. The cells 
were subsequently incubated for 24 h or 48 h before 
the assay. To perform the assay, 20 μL of MTT reagent 
was added to each well and incubated for another 
four hours. 150 μL of dimethylsulfoxide (DMSO, Sigma) 
was then added to dissolve the precipitate with 5 min 
gentle shaking. Absorbance was then measured with 
a microplate reader (Bio-Rad) at the wavelength of 
490 nm. The cell viability was obtained by normalizing 
the absorbance of the sample against the control well 
and expressed as percentage, assigning the viability 
of non-treated cells as 100%. Assays were performed 
in triplicate and the results were averaged. 
2.3 Transfection, flow cytometry measurement and 
cell imaging 
MiaPaCa-2 cells (1 × 104) were seeded onto six-well 
plates in DMEM medium without antibiotics to give 
30–50% confluence at the time of transfections. 
Phos-10% and F127-10% nanoparticles were mixed 
with 20 μL of 10 μM K-ras siRNA (Sense: 5’-FAM- 
GUUGGAGCUUGUGGCGUAGUU-3; Antisense:  
5-CUACGCCACAAGCUCCAACUU-3,) with gentle 
vortex and incubated for 20 minutes. Before transfec-
tion, the culture medium was replaced with FBS-free 
DMEM medium, the above mentioned nanoparticle- 
siRNA nanoplex formulations were then added to the 
six-well plate wells and the cells were continuously 
cultured. For flow cytometry analysis, cells were 
digested by trypsin after 24 hours of transfection and 
washed twice with phosphate-buffered saline (PBS). 
Samples were analyzed using a FACSCalibur flow 
cytometer (Becton Dickinson, Mississauga, CA). In 
vitro fluorescence microscopy images were obtained 
using fluorescence microscope (Eclipse-Ti, Nikon) 
with appropriate fluorescent filter cubes. After 4 h of 
incubation, the nanoplex transfected cells were washed 
twice with PBS, and fixed with 4% formaldehyde. 
The cell nuclei were stained with 4',6-diamidino-2- 
phenylindole (DAPI) (Sigma). For both flow cytometry 
analysis and fluorescent imaging, siRNAs were labeled 
with fluorescent FAM. 
2.4 Gene expression analysis 
Forty-eight hours after transfection, total RNA was 
extracted from MiaPaCa-2 cells using a E.Z.N.AtM 
Total RNA Kit (OMEGA) and the amount was quan-
titated by a spectrophotometer (Nano-Drop ND-1000). 
Reverse transcription was conducted in a 20 μL reaction 
mixture and cDNA was synthesized from 2 μg of total 
RNA using the reverse transcriptase kit (Promega) 
according to the previous experience [33]. The K-ras 
relative mRNA expression level was determined using 
quantitative real time qRT-PCR normalized to the 
expression of β-Actin, one of the most commonly used 
housekeeping genes adopted in comparisons of gene 
expression [34]. According to the previous report [35], 
the primer sequences for different genes were as follows: 
K-ras, forwards 5’-AGAGTGCCTTGACGATACAGC-3’ 
and reverse 5’-ACAAAGAAAGCCCTCCCCAGT-3’; 
β-Actin, forwards 5'-CGGAACCGCTCATTGCC-3’ and 
reverse 5'-ACCCACACTGTGCCCATCTA-3’. 
2.5 Animal maintenance and pathological study 
BALB/C mice were obtained from the Medical 
Laboratory Animal Center of Guangdong Province and 
handled with protocols approved by the Laboratory 
Animals Center of Shenzhen University. All the animal 
experiments and maintenance were approved by the 
Experimental Animal Ethics Committee of Shenzhen 
University. BALB/C mice were obtained at 8 weeks  
of age and were housed 5 per cage in a 12 h/12 h 
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light/dark cycle. All animals were fed with water and 
standard laboratory chow ad libitum. The mice were 
injected with 200 μL of buffer saline or buffered 
nanoparticle dispersions. At different periods after 
injection the mice were weighed and evaluated for 
behavioral changes. For pathological analysis, the 
animals were sacrificed after 42 days of treatment. 
The major organs (heart, liver, spleen, lung, kidney 
and brain) of the mice were harvested and embedded 
in paraffin, sectioned, and stained with hematoxylin 
and eosin (H&E staining). The H&E staining slices 
were examined under an optical microscope (Olympus 
BX51) by a clinical pathologist. 
3 Results and discussion 
In our study, two different polymer materials, namely 
PEGylated phospholipid and Pluronic F127, were used 
to encapsulate the AIE dye and create the polymer- 
based fluorescent nanoparticles. The encapsulation 
process is straightforward and the steps are schema-
tically illustrated in Fig. 1. Two different loading 
ratios of 10% and 5% of AIE dye molecules were  
used to synthesize dye-loaded nanoparticles and  
this strategy has allowed us to generate four types  
of nanoparticle formulations which are referred as 
Phos-10%, Phos-5%, F127-10% and F127-5%. Figure 2 
shows the extinction and photoluminescence (PL) 
spectra of the different types of nanoparticle formula-
tions. Similar extinction spectra features were observed 
for both AIE dye-loaded nanoparticles dispersion and 
“free” dyes in chloroform solution. However, this is 
not the case for the PL spectra. The emission peak of 
the AIE dyes red-shifted from 620 to 660 nm after they 
were loaded into polymer nanoparticles and this 
indicates that the AIE dyes are aggregated in the 
particle cores. This observation is consistent with pre-
vious reports. The fluorescent quantum yields (QY) 
of the encapsulated nanoparticles were estimated to 
be around 6.4% and 12.6% for Phos-5% and Phos-10% 
formulations, respectively. Similar QY values of 6.7% 
and 12.9% for F127-5% and F127-10% were also 
observed. Figure 3 shows the hydrodynamic size 
distribution of the prepared nanoparticles. It has been 
reported that the aggregation number of micelles is 
affected by several factors such as the amphiphile  
 
Figure 1 Schematic illustration of the construction of nano-
particle formulations based on PEGylated phospholipid and triblock 
co-polymer Pluronic F127. 
 
Figure 2 Extinction and photoluminescence spectra of the AIE 
dye in chloroform and encapsulated in polymer nanoparticles. 
material itself, temperature, counterion radius and 
ionic strength [36, 37]. In our case, the phospholipid 
micelle encapsulated AIE dye nanoparticles have a 
larger hydrodynamic diameter size when compared 
to Pluronic F127 encapsulated AIE dye nanoparticles. 
It is worth noting that the phospholipid micelle 
encapsulated AIE dye nanoparticle size is dependent 
on the dye concentration loaded within the particle. 
As organic additives generally decrease the aggregation 
number of a micellar system [36], this could explain 
why the average hydrodynamic particle size for the 
Phos-10% (165.2 nm) is smaller than the Phos-5% 
formulation (190.4 nm). On the other hand, although 
the aggregation pattern of the triblock co-polymer 
Pluronic F127 is very different from that of the 
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phospholipid micellar system [38–41], we observed 
that the loaded dye concentration did not affect the 
average size of the nanoparticles. The measured sizes 
were 140.3 nm and 137.5 nm for F127-10% and F127-5%, 
respectively. 
Prior to embarking on the gene delivery study, the 
cytotoxicity of the prepared nanoparticle formulations 
was examined by using cell viability assay. As shown 
in Fig. 4, the cell viability of MiaPaCa-2 cells remained 
around 80% after treatment with the prepared for-
mulations at different dosages. The result shows that 
both the phospholipid micelle and the Pluronic F127 
encapsulated AIE dye nanoparticle formulations have 
relatively high biocompatibility within the tested 
dosage range in this experiment. However, we did 
notice that the cells treated with the phospholipid 
micelle encapsulated dye nanoparticle formulation 
have a slightly lower viability compared to the cells 
treated with the Pluronic F127 micelle-encapsulated 
dye particle formulation. This may be due to the 
release of the AIE dye molecules from the micelle 
particles or/and the toxicity of the micelle particles. 
 
Figure 3 Hydrodynamic size distribution of different AIE dye encapsulated formulations. (a) Phos-10%, PEGylated phospholipid 
encapsulated AIE dye nanoparticles with a feeding ratio of 10 wt.%. (b) Phos-5%, PEGylated phospholipid encapsulated AIE dye 
nanoparticles with a feeding ratio of 5 wt.% (c) F127-10%, Pluronic F127 encapsulated AIE dye nanoparticle with a feeding ratio of 10 wt.%.
(d) F127-5%, Pluronic F127 encapsulated AIE dye nanoparticles with a feeding ratio of 5 wt.%. 
 
Figure 4 Relative cell viabilities of MiaPaCa-2 cells treated with different concentrations of the four nanoparticle formulations, after 24 h
(a) or 48 h (b) of treatment. 
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As reported by Wang et al., the release rate of dyes 
from micelle particles becomes higher as the con-
centration of the loaded dye increases [42], and the 
free dye becomes a major source of the toxicity in the 
biological system. The other toxicity source is the 
PEGylated phospholipid micelle particles themselves. 
Wang et al. have shown that PEGylated phospholipid 
micelles can induce endoplasmic reticulum-dependent 
apoptosis of cancer cells [43]. They found that the 
PEGylated phospholipid micelle particles were 
accumulated in the endoplasmic reticulum (ER) and 
disturb the ER lipid homeostasis, thus causing ER 
stress to the cancer cells. Under such stress, the cancer 
cells initiate proapoptotic signaling and undergo ER 
membrane damage which in turn triggers the caspase- 
dependent apoptosis process. It is worth mentioning 
that during the nanoparticle preparation process, 
chloroform was introduced; this is classified as a group 
2B carcinogen by the International Agency for Research 
on Cancer (IARC) [44]. However, as the cytotoxicity 
effects of chloroform are reported to be observed at a 
relatively high concentration of above 4 mM in female 
rat hepatocytes [45], the trace amount of chloroform 
in this study was not the main contributing factor to 
the differences in the cell viabilities between the 
Pluronic F127 and phospholipid formulations. 
To conjugate siRNAs for intracellular gene delivery, 
it is required that the nanoparticles have a positively 
charged surface. The prepared micelle-encapsulated 
AIE dye nanoparticles in this study are negatively 
charged due to the PEGylated surface of the particles. 
To reverse the surface charge of the particles, a 
positively charged polyelectrolyte poly(allylamine 
hydrochloride) (PAH) was added to the nanoparticle 
surface through a layer-by-layer assembly process. 
Figure 5 shows the zeta potential of the four nano-
particle formulations before and after PAH modifi-
cation. The charge reversal from negative to positive 
clearly reveals the successful coating of PAH on the 
nanoparticle surface. As a demonstration, the two 
formulations with higher dye doping ratios, Phos- 
10% and F127-10%, were used as nanocarriers for 
siRNA delivery studies. SiRNAs targeting the mutant 
K-ras gene of MiaPaCa-2 cells were complexed to  
the micelle-encapsulated AIE dye nanoparticles 
through electrostatic interaction. These two nanoplex  
 
Figure 5 Zeta potential values of the four formulations before 
and after PAH assembling 
formulations, referred as Phos-10%-siRNA and F127- 
10%-siRNA, were used for transfection of MiaPaCa-2 
cells. Figure 6 shows the fluorescent images of cells 
treated with Phos-10%-siRNA and F127-10%-siRNA 
nanoformulations, where the siRNAs were labeled 
with a fluorescent tag FAM for monitoring the bio-
distribution of the nanoparticles. From the fluorescent 
images, one can observe that both formulations have 
successfully delivered siRNAs into the cancer cells, 
and this is confirmed by the co-localization of the red 
(AIE dye) and green (siRNAFAM) fluorescent signals 
around the cell nucleus. In contrast, no green signals 
were detected from cells treated with free siRNAs (data 
not shown). The endosomal escape and siRNA release 
from the nanocarriers are the two key steps that siRNA- 
based RNAi needs to carry out efficiently. Several 
mechanisms have been reported to be responsible for 
the endosomal escape, such as the pore formation in 
the endosomal membrane, pH-buffering effect, endoso-
mal membrane fusion and photochemical disruption of 
the endosomal membrane [46, 47]. For example, some 
viruses tend to escape through a fusion process, where 
conformational changes of fusogenic peptides are 
involved in inducing the fusion in the lipid bilayers of 
the endosomes [48, 49]. Similarly, the cationic liposomes 
are able to escape from the endosomes based on this 
pathway [50]. They usually introduce a neutral helper 
lipid, such as dioleoylphosphatidylethanolamine 
(DOPE), to enhance the fusion between the liposomes 
and the endosomal membrane [51, 52]. The pH- 
buffering effect, also known as the proton sponge effect, 
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is another endosomal escape mechanism which is 
commonly adopted in designing the transfection 
agent to assist the payload release [53]. In such process, 
a positively charged polymer—such as polyethylenimine 
[54] or poly(amidoamine) [55]—or methylamine [56], is 
usually used to modify the surface of the transfection 
agent, in order to induce the extensive inflow of  
ions and water into the endosomal environment to 
break the endosomal membrane, thus setting free the 
substances encapsulated within the particle. The PAH 
used in this study is a positively charged polymer 
with an abundance of primary amine groups. Based 
on these facts, formulation takes place, the PAH 
causes the inflow of ions into the endosomes, and 
subsequently induces the endosomal escape of the 
nanoplexes through proton sponge effects. From the 
fluorescence images, we can clearly identify the red 
and green signals. Since naked siRNAs cannot enter 
the cells without any transfection agents, this indicates 
that the siRNA molecules have detached from the 
nanoplex particles and gradually diffused into the local 
cytoplasm environment to initiate the RNAi process. 
To quantify the siRNA transfection efficiency of the 
nanoparticle formulations, flow cytometry analysis 
was performed. In this experiment, a reference gate 
(Fig. 7(a)) was used to exclude the cell debris and the 
fluorescent dot-plots were divided into four different 
zones using the blank control as reference (Figs. 7(b)– 
7(d)). As shown in Fig. 7(c), most of the Phos-10%- 
siRNA treated cells displayed red fluorescence 
originating from the AIE dye, and the fluorescence 
from the FAM label is relatively weak. In comparison, 
the cells treated with F127-10%-siRNA have strong 
fluorescent signals from the FAM label (Fig. 7(d)). 
The statistical results of the flow cytometry analysis 
are summarized in Fig. 7(e). The transfection efficiency 
is defined as the population of FAM-positive cell 
counts and the labeling efficiency is defined as the 
cell counts displayed by fluorescence from the AIE 
dye. Our results show that both the phospholipid and 
Pluronic F127 micelle-encapsulated AIE dye nano-
particle formulations are able to serve as nanocarriers 
for transfecting the cells with siRNAs molecules. The 
Phos-10%-siRNA formulation has a relatively high 
labeling efficiency when compared to the F127- 
10%-siRNA formulation. However, it possesses 
relatively lower transfection efficiency (41.3 ± 0.26%) 
when compared to the F127-10%-siRNA formulation 
(78.5 ± 0.21%). As the two particle formulations have 
different aggregation patterns, the kinetic release 
rates of siRNAs from the nanoplexes are different 
from one another. It was reported that a burst release 
of 20–30% siRNA was observed in the first 24 hours 
in an in vitro study involving the use of a polyeth-
ylenimine (PEI) modified PLGA nanoparticle formula-
tion [57]. In addition, the fusion of phospholipid 
 
Figure 6 Fluorescent imaging of MiaPaCa-2 cells treated with AIE dye doped nanoparticle formulations. (a) Blank control, (b) Phos-10%
and (c) F127-10%. The FAM labeled siRNAs and AIE dye were rendered in green and red, respectively. Cell nuclei are stained with 
DAPI and rendered in blue. 
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molecules with the endosomal membrane accelerated 
the disruption of the particle and subsequent release 
of siRNA molecules [58, 59]. These two key factors may 
have contributed to the low transfection efficiency of 
the Phos-10%-siRNA formulation. To investigate the 
gene silencing efficiency of the nanoplexes, the K-ras 
mRNAs expression of the cells was measured by 
quantitative real time PCR. As shown in Fig. 8, both 
the Phos-10% and F127-10% nanoformulations showed 
effective knockdown of the mutant K-ras gene, with 
efficiencies of 83.52 ± 2.45% and 74.96 ± 1.41%, 
respectively. The down regulation of gene expression 
confirms the successful siRNA transfection by the 
nanoparticle formulations. This indicates that the  
 
Figure 7 Flow cytometry analysis of MiaPaCa-2 cells transfected with Phos-10% and F127-10% formulations. (a) Reference gate 
definition. Dot plots of cells treated with saline (b), Phos-10% (c) and F127-10% (d). (e) Statistical evaluation of the dot plots showing 
the transfection and labeling efficiency. 
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Figure 8 K-Ras mRNA relative expression levels detected   
by quantitative real time RT-PCR in MiaPaCa-2 cells treated  
with Phos-10% or F127-10% formulation, as compared with non- 
treated control. 
siRNAs are delivered into the cells and released in 
the cytoplasm, and then subsequently bind to the 
targeting mRNA thus initiating the gene silencing 
process. To date, many mutations in pancreatic 
cancer have been found in human genes [60], such as 
HER2/neu [61], p16INK4 [62], p53 [63] and BRCA2 [64], 
but K-ras oncogene has been identified as having the 
highest alteration frequency and it usually starts to 
develop in the early stages of pancreatic cancer [65, 66]. 
More importantly, the mutation of K-ras oncogene is 
associated with a series of downstream gene regulation 
that is related to the proliferation, migration and 
invasion of pancreatic cancer cells [67, 68]. In vitro 
studies have found that silencing of the mutant K-ras 
in pancreatic cancer through RNAi methods promotes 
cell apoptosis [69–72], and inhibit cell proliferation 
[73, 74], migration [75] and invasion of the tumor 
cells [76]. Thus, the use of micelle-encapsulated AIE 
dye nanoparticles for down regulating the K-ras  
gene expression of pancreatic cancer will be a useful 
approach in the near future for effective therapy of 
pancreatic cancer in vivo.  
In addition to an in vitro study, we also tested the in 
vivo biocompatibility of our prepared nanoformulations. 
In this experiment, all of the four polymer-encapsulated 
AIE dye nanoparticle formulations—Phos-10%, Phos- 
5%, F127-10% and F127-5%—were intravenously 
administered to BALB/C mice at a relatively high 
dosage of 1.5 mg·kg–1. The treated mice were monitored 
for over six weeks and no significant changes in body 
weight were observed in the experimental groups 
when compared to the control group that received  
 
Figure 9 Body weight change of mice treated with different 
nanoparticle formulations. 
only buffer solution (Fig. 9). Also, histological analysis 
was performed on the tissue sections obtained from 
the major organs of the mice after six weeks of nano-
particle treatment (Fig. 10). All the tissue sections 
including the heart, liver, lung, spleen, kidney and 
brain were carefully evaluated by a pathologist. Normal 
hepatocytes were observed in the liver sections and 
no inflammatory response was identified. Red pulp 
and white pulp structure features were clearly observed 
in the spleen tissue section and no infiltration of 
granulocytes was detected. No pulmonary fibrosis 
was found in the lung tissue sections and normal 
glomerulus structures were observed in the kidney 
tissue sections. No necrosis was observed in all the 
examined tissue sections. This indicates that both the 
nanoparticle formulations employed here have the 
potential to be translated for clinical research testing of 
pancreatic cancer gene therapy using higher hierarchy 
animal subjects.  
4 Conclusions 
We have synthesized polymer micelle-encapsulated 
AIE dyes nanoparticles as nanocarriers for siRNA 
delivery in pancreatic cancer cells. The AIE dye was 
synthesized by covalently conjugating the ACQ 
chromophore TPA–DCM to an AIE luminogen TPE. 
The resulting TPE–TPA–DCM dye preserves the AIE 
property and shows a strong aggregation-induced 
fluorescence when encapsulated in either the 
phospholipid micelle or Pluronic F127 nanoparticle 
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formulations. The prepared nanoparticle formulations 
were then complexed with siRNAs through layer-by- 
layer assembly for gene delivery therapy of pancreatic 
cancer cells. Our results show that the siRNAs can be 
successfully transfected into the MiaPaCa-2 cells and 
initiate the RNAi process by using the prepared 
nanoparticle formulations as the transfection agents. 
Fluorescence imaging and flow cytometry were used 
to confirm the successful transfection of siRNA. 
Quantitative real time PCR indicated the substantial 
knockdown of the targeted mutant K-ras gene at the 
mRNA level. In addition, we have evaluated the in 
vivo toxicity of the nanoparticle formulations using 
BALB/c mice. For a six-week experimental period, 
mice treated with all four nanoparticle formulations 
at a dosage of 1.5 mg·kg–1 did not show any adverse 
response. Histological analysis of the major organs 
obtained from the treated mice did not reveal any 
observable toxicity effects caused by the dye-loaded 
nanoparticle formulations. Overall, the dye-loaded 
nanoparticle formulations prepared in this study 
have shown promising result for pancreatic cancer 
gene therapy in vitro and we envision that these 
nanoformulations can be employed in clinical research 
applications by further optimizing the surface 
properties of the particle (e.g. by conjugating with 
ligands for targeted delivery). 
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